EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, is now recruiting
Cure Parkinson’s is excited to announce that the first multi-arm multi-stage clinical trial platform for Parkinson’s in the UK – EJS ACT-PD – is underway, with recruitment now open to people with Parkinson’s. The Edmond J. Safra Accelerating Clinical Trials for Parkinson’s Disease (EJS ACT-PD)...
Learn more
New findings from the TransEuro cell replacement trial are now published
Parkinson’s is characterised by the progressive loss of dopamine nerve cells (neurons) in an area of the brain associated with movement. Therefore, researchers have been investigating whether cell transplantations have potential to replace the neurons lost, to slow or reverse progression of the condition. What…
Paws for Parkinson’s: April Dog Walking Challenge raises over £39k for Cure Parkinson’s
Over 130 supporters and their dogs got out in the spring sunshine to take part in our 2025 April Dog Walking Challenge! For the past three years our supporters and their four-legged friends have ventured outdoors during the month of April to help fundraise for…
Over £268k raised for Cure Parkinson’s at the 2025 TCS London Marathon
On Sunday 27 April, 42 incredible Cure Parkinson’s supporters completed the grueling 26.2 mile race. Team Cure were battling the heat at the 45th London Marathon, but despite the difficult conditions each and every one of our determined runners crossed the finish line. Of the…
TCS London Marathon 2026
The unbeatable atmosphere of the London Marathon makes this race one of the best in the world. Please note applications for charity places are now closed. We are currently reviewing all applications and hope to allocate places in August. Before you apply, here’s what you...
Cure Parkinson’s welcomes a new research committee chair
Every research project that Cure Parkinson’s funds must be recommended by our research committee – an independent board of leading Parkinson’s researchers, clinicians, people with Parkinson’s, patient advocates and experts in intellectual property and regulatory affairs, who meet four times a year to evaluate new…